Stockscreener 앱 받기
46.07
0.07%
-0.03
시간 외 거래:
46.20
0.13
+0.28%
전일 마감가:
$46.10
열려 있는:
$45.82
하루 거래량:
638.95K
Relative Volume:
1.07
시가총액:
$3.18B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-11.66
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
-2.17%
1개월 성능:
+11.68%
6개월 성능:
-7.86%
1년 성능:
-2.21%
1일 변동 폭
$45.32
$47.21
1주일 범위
$44.39
$47.43
52주 변동 폭
$37.77
$61.61
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
46.07 | 3.18B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
Merus (NASDAQ:MRUS) Short Interest Down 13.5% in February - Defense World
Stifel maintains Buy on Merus stock with $93 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Merus stock with $93 target - Investing.com India
Merus N.V. Reports 2024 Earnings and Clinical Progress - TipRanks
Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025 - Simply Wall St
Merus (NASDAQ:MRUS) Receives “Buy” Rating from HC Wainwright - Defense World
Merus stock holds Buy rating and $85 target from H.C. Wainwright - Investing.com India
Merus stock holds Buy rating and $85 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Merus’ (MRUS) Outperform Rating Reiterated at William Blair - Defense World
Needham & Company LLC Cuts Merus (NASDAQ:MRUS) Price Target to $83.00 - Defense World
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS) - Yahoo Finance
Merus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS - MarketBeat
BMO Capital lifts Merus stock target to $96, maintains Outperform By Investing.com - Investing.com South Africa
BMO Capital lifts Merus stock target to $96, maintains Outperform - Investing.com
Merus Shares Soar Amid Breakthrough Therapy Hopes - TipRanks
Merus NV reports results for the quarter ended December 31Earnings Summary - TradingView
Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond - Nasdaq
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire
Merus Secures FDA Approval for Cancer Drug With $724M War Chest to Fund Operations Through 2028 - StockTitan
Merus N.V. SEC 10-K Report - TradingView
Merus N.V. to Host Earnings Call - ACCESS Newswire
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Oncology Innovator Merus Schedules Two Major Investor Presentations - StockTitan
Merus (MRUS) to Release Quarterly Earnings on Wednesday - MarketBeat
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.
Merus Shares Are Up Today: What's Going On?Merus (NASDAQ:MRUS) - Benzinga
Merus Stock Surges on Breakthrough Therapy News - TipRanks
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com
Objective long/short (MRUS) Report - Stock Traders Daily
Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire
Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan
Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat
Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - MSN
BMO Capital Maintains Merus N.V. (MRUS) Outperform Recommendation - MSN
Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts - Defense World
Piper Sandler sets $84 target on Merus stock, cites drug potential - Investing.com Australia
FY2024 Earnings Forecast for Merus Issued By Leerink Partnrs - MarketBeat
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit -February 13, 2025 at 08:01 am EST - Marketscreener.com
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - The Manila Times
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.81%
자본화:
|
볼륨(24시간):